TABLE 2.

Thymic cell subsets in adult DOX-treated and untreated DTg mice^a

Mouse and founder line	Sex	Total DOX treatment (wks)b	No. of cells (106)				CD4/CD8 ratio	DP CD4 MFI (%)c
			Total	CD4+ CD8−	CD8+ CD4−	CD4+ CD8+
CD4C/rtTA × TRE/HIV
F148571	Male	None	70.66 ± 10	4.74 ± 0.73	1.61 ± 0.62	58.8 ± 6.87	2.94	100
		6	48 ± 3.26*	0.73 ± 0.18**	0.66 ± 0.08*	44.8 ± 2.58*	1.1	67.4 ± 4*
CD4C/rtTA2S-M2 × TRE/HIV
F176042	Male	None	61.4 ± 17.4	2.72 ± 0.78	0.92 ± 0.31	51.8 ± 14.8	2.94	100
		1	6 ± 2.2**	0.59 ± 0.21**	0.18 ± 0.08*	2.8 ± 1.08**	3.22	52.4 ± 20.4
	Female	None	109 ± 13.8	4.99 ± 1.8	1.25 ± 0.53	92.6 ± 13.2	3.98	100
		6	80.5 ± 25.6*	1.72 ± 0.29**	0.42 ± 0.14*	68.5 ± 23.6*	4.02	66.1 ± 6.4***
F176043	Male	None	119 ± 31	5.37 ± 2.03	2.07 ± 0.64	106 ± 27.9	2.58	100
		1	6.75 ± 3.22**	0.27 ± 0.09*	0.08 ± 0.04**	5.35 ± 2.73**	3.15	42.1 ± 9.7***
	Female	None	210 ± 11.5	10.7 ± 2.68	2.4 ± 0.15	180 ± 21.7	4.46	100
		6	202 ± 26.2	5.82 ± 1.74*	1.21 ± 0.18**	172 ± 21.7	4.79	67.7 ± 10.6*

^a*, P < 0.05; **, P < 0.005; ***, P < 0.0005 (by Student's t test).

^bDOX-treated animals received a dose of 2 mg/ml for the indicated time period.

^cMFI, mean fluorescence intensity.